DelMar Reveals Plan for China Trial of Lung Cancer Drug

DelMar Pharma, a Vancouver-Menlo Park, CA company, together with its China partner, Guangxi Wuzhou Pharma, announced plans to start a China Phase IV trial of VAL-083 in patients with refractory and relapsed non-small cell lung cancer. The drug is already approved for NSCLC in China, but most patients are prescribed newer tyrosine kinase inhibitors. Based on preclinical studies, DelMar believes VAL-083 is effective against TKI-resistant NSCLC, which the trial is designed to prove. More details.... Stock Symbol: (OTCQX: DMPI) Share this with colleagues: // //